A clear look at REZOLVE-AA's 52-week alopecia areata findings, the eight-patient follow-up group and Nektar's planned Phase 3 study.
In its report dated 2026-10-02, Dermatology Times described 52-week findings from REZOLVE-AA, the Phase 2b trial of rezpegaldesleukin for severe-to-very-severe alopecia areata. The coverage included hair-regrowth observations during extended treatment and after treatment ended.
The update brings two distinct questions into focus: how responses develop over time and whether an achieved response persists after treatment stops. Reading those findings requires attention to who was measured at each stage.
According to Dermatology Times, REZOLVE-AA was a global Phase 2b study that randomized 92 patients with severe-to-very-severe alopecia areata. Participants had not previously received a JAK inhibitor or another biologic. The initial treatment period included placebo and two rezpegaldesleukin dose groups.
Study presenter David Rosmarin told Dermatology Times that more patients achieved improved hair-regrowth results with continued treatment from Week 36 to Week 52. He also said some patients' responses had not yet plateaued as they approached Week 52.
Improvement during treatment and maintenance after treatment are different outcomes. The first concerns a response while the drug is being given. The second concerns what happens once it is no longer being given. A report covering both needs to keep those questions separate.
Dermatology Times explains that a SALT score of 20 or lower corresponds to at least 80% scalp hair coverage. This is a threshold for scalp coverage in an individual patient. It is not the proportion of trial participants who responded.
The outlet reported the following observations among eight patients who completed 52 weeks and achieved SALT ≤20:
These are maintenance figures for patients who had already achieved the specified response. They answer a narrower question than the overall likelihood of reaching that response after starting treatment.
Outcomes in routine care may differ from those observed in a controlled trial. For readers, the useful habit is to pair every percentage with its patient count and the outcome being measured.
According to Dermatology Times, the Week 36 to Week 52 extension included selected participants who still had a SALT score above 20 and had shown hair growth at Week 36. Those participants could continue their assigned dose for 16 additional weeks.
This was not the full randomized group. Results from that selected extension should not be presented as outcomes for all 92 participants. The eligibility rules matter because they define which patients contributed to the later observations.
The maintenance result rests on only eight responders. Dermatology Times did not supply confidence intervals or p-values for those findings. The reported follow-up also does not establish how long responses last beyond six months off treatment.
The numerical findings discussed here come from conference coverage and company communications, rather than a full peer-reviewed results paper identified in this update. Rosmarin's comments about continued improvement are the presenter's interpretation, not an independent comparative assessment.
Nektar Therapeutics characterized the 52-week safety profile as favorable and consistent with earlier findings. However, the conference coverage did not provide detailed adverse-event rates. A favorable description is not a substitute for knowing how frequently adverse events occurred, and the duration of observation alone does not establish long-term safety.
For someone discussing severe alopecia areata with a qualified clinician, the practical distinction is between an approved treatment and an investigational one. Nektar describes rezpegaldesleukin as investigational. The reported findings are not a basis for starting, stopping or changing an alopecia areata treatment.
A useful clinical conversation can consider how the study population relates to a person's treatment history and which approved options fit their circumstances. Questions about changing or interrupting treatment belong in that individualized discussion, rather than being settled by an off-treatment percentage.
For broader context, Younell's guide to understanding alopecia areata over time provides a place to read about recognition and long-term management. Our separate look at pooled oral JAK inhibitor research offers another treatment-evidence topic to consider without treating different studies as direct comparisons.
For readers whose concern is general hair thinning, the scope of this report is equally important: it studied severe-to-very-severe alopecia areata. It should not be treated as evidence for every type of hair-density concern.
Nektar says its planned Phase 3 ZENITH-AA study is expected to enroll 850 people with severe-to-very-severe alopecia areata and begin in early 2027. The company identifies SALT ≤20 at Week 52 as the primary endpoint.
That announcement describes the next planned test, not a completed result. Its importance lies in the opportunity to examine the treatment in a larger study with a clearly defined regrowth target.
The central question is whether further research will support a useful balance of sustained scalp-hair regrowth and a well-characterized safety profile. For now, the REZOLVE-AA update is a reason to follow the evidence, not a promise about an individual's outcome.
Stay connected for research and practical guidance on skin, hair, collagen, nutrition and beauty longevity. Clear ideas for people who want to understand how appearance changes with age and make better-informed choices over time.
Understand your skin, hair and body better without chasing every new trend, treatment or promise.
explore the Blog
